Shop

The Ann Arbor News investigated an alleged cover-up of concerns about the side effects of a new diabetes drug - Rezulin - prior to its approval by the Food and Drug Administration. The investigation revealed that "it took at least 63 deaths over 2 1/2 years to convince the FDA and Parke-Davis [the producing company, based in Ann-Arbor] to finally pull Rezulin off the market." The reporter found out that "pre-approval data from Parke-Davis had suggested the possibility of liver problems," but the producer didn't "point this data out to the FDA, and the FDA ignored or covered up this concern." The series raised questions about conflicts of interest, stemming from the fact that "some members of the FDA committee of doctors who approved Rezulin, as well as a top decision maker....had worked as paid consultants for Parke-Davis..." The stories questioned the proper work of the country's drug approval system.